Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV001000875 | SCV001157956 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2018-10-26 | criteria provided, single submitter | clinical testing | The SGCA c.115A>G; p.Thr39Ala variant (rs540292629), to our knowledge, is not reported in the medical literature or gene specific databases. This variant is found in the African population with an allele frequency of 0.063% (15/23,996 alleles) in the Genome Aggregation Database. The threonine at codon 39 is weakly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is tolerated. Due to limited information, the clinical significance of the p.Thr39Ala variant is uncertain at this time. |
Labcorp Genetics |
RCV001000875 | SCV001419902 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2022-04-29 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with alanine, which is neutral and non-polar, at codon 39 of the SGCA protein (p.Thr39Ala). This variant is present in population databases (rs540292629, gnomAD 0.06%). This variant has not been reported in the literature in individuals affected with SGCA-related conditions. ClinVar contains an entry for this variant (Variation ID: 811177). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002549144 | SCV003535172 | uncertain significance | Inborn genetic diseases | 2021-07-14 | criteria provided, single submitter | clinical testing | The c.115A>G (p.T39A) alteration is located in exon 2 (coding exon 2) of the SGCA gene. This alteration results from a A to G substitution at nucleotide position 115, causing the threonine (T) at amino acid position 39 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV001000875 | SCV003827590 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2021-11-29 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001000875 | SCV003931631 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2023-02-08 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003479261 | SCV004223001 | uncertain significance | not specified | 2023-11-21 | criteria provided, single submitter | clinical testing | Variant summary: SGCA c.115A>G (p.Thr39Ala) results in a non-conservative amino acid change located in the Dystroglycan-type cadherin-like (IPR006644) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 3.6e-05 in 251454 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.115A>G in individuals affected with Limb-Girdle Muscular Dystrophy, Autosomal Recessive and no experimental evidence demonstrating its impact on protein function have been reported. Six submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Natera, |
RCV001000875 | SCV002087548 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2020-02-21 | no assertion criteria provided | clinical testing |